Father-of-two sheds 16 stone in under a year after kicking thrice-daily addiction... without weight loss jabs
Dale Forrest, 36, from Bolton, fell into a trap of unhealthy eating—gorging on three pasties a day for lunch—battling with poor mental health, an inactive lifestyle and a job he hated.
But, when he saw his wedding photos after marrying his wife, Kat, in September last year, he knew something had to change.
'I used to be so miserable, feeling guilty but living a lazy lifestyle.
'When I saw the wedding pictures, I thought I looked horrific and the first thing I said to my wife was I need to make a change.'
As well as scoffing three pasties for lunch, the father-of-two would put away a Greggs for breakfast and a Papa John's Pizza for dinner before heading to the pub for several pints.
The office worker had previously made an impressive effort to lose the weight over a decade ago—which saw him give up alcohol and lose a mammoth 14 stone.
But, after suffering with poor mental health, his confidence plummeted and the weight piled back on.
'I was living alone in a studio apartment, all my mates had girlfriends, wives and kids and I was just lonely,' he recalled.
'I also didn't like my job at the time. As soon as I put a little weight back on, everything just spiraled.'
At his heaviest, Mr Forrest weighed 32 stone and sported size 6XL t-shirts.
Then, after meeting his wife Kat in 2021 and having two children, Bailey, 3, and Tate, 1, Mr Forrest began to notice improvements to his mental health—but it wasn't enough to drop the weight.
But after receiving their wedding photos on September 17, the 'embarrassment' gave the father-of-two the push he needed to get back on track.
He said: 'As soon as I saw them I just had to make a change.
'The first thing I did was bin all the snacks in the house so they weren't there to tempt me. Then I started my diet.'
Determined to lose the weight and keep up with his two growing children, Mr Forrest tried a calorie-restrictive diet designed for sustainable weight loss—consuming just 1,500 calories a day for a month.
'I was so unhealthy to the extent that I couldn't walk 100 metres before feeling tired,' he recalled.
'I knew I wouldn't be able to exercise until I had lost some initial weight.'
According to the NHS, as a guide an average man needs 2,500 kilocalories a day—though this can vary based on age, weight, height and exercise levels.
When trying to lose weight, the health service suggests reducing daily calorie intake by around 600kcal.
Just a month later, the father-of-two had lost two stone, giving him the confidence to add exercise into his daily routine aiming for 10,000 steps a day to build up his fitness levels.
Then in December, having dropped 7 stone, the office worker decided it was time to implement a more structured workout routine.
'Going to the gym at that weight even though I had done it before was terrifying,' he said.
'I thought everyone was looking at me thinking "why is this guy here".
'I was self-conscious of my body, but especially my legs,' he added.
Mr Forrest, who has his eyes set on a charity boxing competition this September, said: 'I wanted to see what I could do naturally and what was possible'.
Despite starting his fitness journey when the likes of Mounjaro and Ozempic were bursting on to the weight loss scene, Mr Forrest said he didn't feel the need to use them.
After starting with cardio and light weights, before progression to heavier weights and boxing, the father-of-two found he was able to drop around a stone a month—now weighing a healthy 15 stone.
He added: 'When the weight started dropping just through diet alone, it made me realise I could do it without [the] support [of weight loss jabs].'
'I did this the hard way, without the use of jabs or anything. Goold old fashioned exercise and diet got me here, no shortcuts.'
Now, the weight loss influencer, who boasts over 3,000 followers on TikTok, is looking to shed another two stone before September as he inspires others to start their own weight loss journey.
'I can now play with my children as before I used to tell them to play with their mum.
'It's nice when they ask:"Daddy, can you put me on your shoulders", and I can be there for them.
'I like to downplay my achievement, but secretly I'm buzzing. I'm now so energetic I can't sit still, I always want to be doing something.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
11 minutes ago
- The Independent
Patients whose lives were ruined after being ‘needlessly given cancer drug for years' sue NHS trust
More than 20 patients who say their quality of life was wrecked when they were needlessly given a highly toxic cancer drug are suing the NHS trust involved. Some people were prescribed temozolomide – which should normally be used for only six months – for more than a decade during treatment by the University Hospitals Coventry and Warwickshire NHS Trust. They say the overprescribing left them with side-effects including secondary cancers and crippling fatigue. Earlier this year the Care Quality Commission was looking into at least 14 cases, but lawyers say more are emerging all the time. An investigation by lawyers Brabners found that, over the past two decades, numerous patients with brain and spinal tumours under the care of Professor Ian Brown were routinely exposed to prolonged and in some cases 'unnecessary' use of the chemotherapy drug, which has severe side-effects including extreme fatigue, confusion, sickness and seizures. The time periods temozolomide was given for allegedly ran contrary to medical and scientific guidelines. Standard NHS procedure is to use the drug over six months, and the drug manufacturer advises it be used for up to 12 months. One man said he was prescribed it for nearly two years longer than necessary, suffering extreme fatigue and low mood as a result. A woman in her twenties said she was misdiagnosed with cancer, receiving the drug needlessly for about eight years. Some patients are now having treatment for secondary cancers allegedly linked to overuse of temozolomide, the lawyers claim. Others claimed its prolonged use left them unable to pursue career ambitions and normal day-to-day activities because the chemotherapy was debilitating, with a long recovery time. Some reported loss of fertility or abnormal blood test results. The legal team says data shows that the trust's spending on the drug of £3.6m from 2009 to 2024 is 10 times that of other NHS oncology departments. The lawyers are now calling for an extended patient safety review and independent investigation, focusing in particular on treatment received by patients under Prof Brown dating back to 2006. The trust has been conducting an internal patient safety review, covering 2017 to 2023, when Prof Brown retired. A patient who identified only as Michael received an extra 22 cycles of temozolomide at the trust, despite his scans being stable. Prof Brown was not present during consultations, and Michael said he was always seen by a clinical nurse specialist. After suffering extreme fatigue and low mood, he learnt through news reports of mistreatment –not from the trust – that he should not have remained on treatment for so long, according to his lawyers. Another patient, identified only as Becky, says she received at least 100 cycles of the drug unnecessarily after being misdiagnosed with a brain tumour. Fiona Tinsley, head of medical negligence at Brabners, said: 'The extent of this scandal, and the physical and mental impact it has had on Prof Brown's patients cannot be underestimated.' She added: 'We believe there are many more patients out there who haven't yet come forward and some who may have sadly passed away. 'While we welcome the ongoing investigations being undertaken by the General Medical Council and Royal College of Physicians, we believe a full independent inquiry is necessary – including an extension of the trust's own review back to 2006 – not only to ensure justice for victims, but that processes are put in place to better identify and prevent such failings happening again.' A spokesperson for the trust told The Independent: 'We have comprehensively reviewed and spoken to all individuals who were receiving temozolomide (TMZ) treatment at the end of 2023 to ensure appropriate support and care plans are in place. 'A glioblastoma is an aggressive brain tumour with fewer than two per cent of patients surviving longer than 10 years. This is an extremely complex condition and all modes of treatment – surgery, chemotherapy and radiotherapy – carry the risk of complications and side-effects. 'National Institute for Health and Care Excellence (Nice) guidelines recognise that clinicians can exercise professional judgment appropriate to individual circumstances when offering treatment to patients. 'We have commissioned the Royal College of Physicians to conduct an independent review of a representative cohort of patients who received greater than 12 cycles of adjuvant TMZ between 2017 and 2023. 'As this process is ongoing, it would be inappropriate to comment further at this stage." It's understood that CQC inspectors have been in touch with the trust to understand the details, and seek assurances that patients are not at risk. The regulator will be reviewing more information to judge whether it needs to be involved.
Daily Mail
41 minutes ago
- Daily Mail
The priming skin serum that banishes breakouts to leave skin glowing - and it uses a VERY unique ingredient: 'My skin has never looked so clear'
Daily Mail journalists select and curate the products that feature on our site. If you make a purchase via links on this page we will earn commission - learn more Clear skin can be difficult to achieve, especially if you have blemishes. You might find that you're either dealing with a breakout or the marks left behind. Both of those concerns are a job for the 47 Skin Anti-Blemish and Scar Repair Serum. This powerful serum takes no prisoners, working on contact to kill off 99.9 percent of the bacteria responsible for blemishes. There's nothing else like it, and it's all thanks to the unique compound known as Silver Chitoderm. 47 Skin Anti-Blemish and Scar Repair Serum Bacteria can run rampant on your skin, causing stubborn breakouts that are difficult to control. This serum works like a dream, killing 99.9 percent of them to leave skin clearer and brighter. In addition to reducing blemishes and marks, it also imparts moisture to give your skin a softer feel. You can even use it as a makeup primer! The results are astonishing, with many users sharing their impressive before and after results. Buy here Shop The brand harnessed the protective and healing properties of silver and coupled them with Chitoderm, which is formulated to create a protective and supportive barrier on the surface and essentially keep the silver right where it needs to be. Because the silver is concentrated right where you need it, it can target those unwanted marks with precision. Whether your concern is a blemish or a spot, you can rely on it to eradicate the bacteria and leave skin calmer and clearer. According to Dr. Sunil Chopra, a consultant dermatologist who founded the London Dermatology Centre, 'It decreases the production of melanin, which is often elevated in scars, reducing pigmentation over time.' And, unlike so many other treatments formulated to minimize those marks, 47 Skin's formula won't leave skin feeling tight and parched. In fact, it has the opposite effect thanks to ingredients like shea butter that soften skin to leave it feeling smoother and looking plumper. The beauty of the formula is that it works overtime, even doubling as a primer for makeup. That's key, because if you regularly wear makeup, you know how helpful primer can be — but very few offer the powerhouse skin care benefits that this serum delivers. The proof is in the consumer studies consisting of over 9,300 participants. Of those, a whopping 94 percent said they would buy the serum again, while 92 percent experienced a reduction in their spots. A whopping 90 percent said they had fewer scars, too. It's proven so effective that users have shared jaw-dropping before and after images revealing clarity and a brighter complexion. 'This is an excellent product. It has really smoothed out my complexion. The delivery was quick to boot. Very pleased,' raved one shopper. 'The acne has visibly decreased, as have my scars and uneven skin tone,' shared another. 'Overall it just looks so much better.' A third customer summed it up perfectly, stating: 'My skin has never looked so clear.' If you're chasing results like those, the 47 Skin Anti-Blemish and Scar Repair Serum could be just what your routine needs!
Medical News Today
an hour ago
- Medical News Today
Muscle loss from GLP-1 drugs like Ozempic may not be as high as thought
While past studies show that adults taking a GLP-1 medication can lose between 5-15% of their starting body weight, other research reports that a good portion of that weight loss comes from muscle loss. A new study says, via a mouse model, that muscle loss from GLP-1 medications like Ozempic may not be as high as recently thought. Researchers also found that the decrease in lean muscle mass was not all from skeletal muscles, but from other body tissues, including the polls estimate that one in every eight adults in the U.S. have taken a glucagon-like peptide-1 receptor agonist (GLP-1) — a class of prescription drugs originally used to treat type 2 diabetes that has gained popularity as a method of weight of GLP-1 medications include semaglutide, sold under the brand names Ozempic and Wegovy, and tirzepatide, sold under the brand names Zepbound and Mounjaro. Past studies show that adults taking a GLP-1 medication can lose between 5-15% of their starting body weight within one year. However, other research reports that about 25-39% of that weight loss is from muscle loss. Now, a new study recently published in the journal Cell Metabolism says, via a mouse model, that muscle loss from GLP-1 medications like Ozempic may not be as high as recently thought. Researchers also found that the decrease in lean muscle mass was not all from skeletal muscles, but from other body tissues, including the liver. Lean muscle mass loss not just from skeletal musclesFor this study, researchers used a mouse model to determine how GLP-1 medications like Ozempic affected lean muscle mass. Upon analysis, researchers found that Ozempic-related weight loss in mice resulted in a lean muscle mass decrease of about 10%, which is less than some previous studies report that as the mice lost weight, some skeletal muscles did decrease, while other muscles stayed the same. Researchers state that the muscle mass decrease is a return to baseline, as gaining fat is usually accompanied by a gain in skeletal muscle. Researchers found some mice experienced a decrease in strength in skeletal muscles that stayed almost the same researchers found that a good portion of the decrease in lean muscle mass did not come from skeletal muscles, but rather other tissues in the body, such as the liver, which they report reduced in size by almost half. It is not uncommon for the liver to decrease in size during weight loss, which can help reduce a person's risk for fatty liver disease.'If we want to really help the individuals who may be losing muscle mass, then we need to know that they're actually losing muscle mass,' Katsu Funai, PhD, associate professor of nutrition and integrative physiology in the University of Utah College of Health and the senior author on the study says in a press release. 'We have data in mice that suggest that things are not as straightforward as they might seem.'Working with a dietitian while taking GLP-1sMedical News Today spoke with Seth Kipnis, MD, FACS, FASMBS, director of bariatric and robotic surgery at Hackensack Meridian Jersey Shore University Medical Center in New Jersey, about this study, who commented that a drop in lean muscle mass is expected. Some muscle loss is inevitable'Any patient with a restricted diet and poor nutrition/protein will have a drop in muscle mass. The key of any weight loss program, surgical, medical or GLP-1 is adequate nutrition. Working with a registered dietitian is key to long-term success and avoiding complications of malnutrition.' — Seth Kipnis, MD, FACS, FASMBS'More and more people are taking these medications on a regular basis,' he continued. 'They are working well to control weight. We should know the side effects that can be caused in the long term so that patients can be counseled on how to avoid long-term issues.' Kipnis said he would like to see better long-term data as the next steps in this research. 'And are different outcomes found depending on the prescriber and the type of follow-up,' he added. 'It is our assumption that specialists in weight management and nutrition will have better outcomes than a primary care doctor that treats every disease. Obesity is a unique disease that requires specialists to manage.'Human trials needed to further analyze GLP-1s and muscle lossMNT also talked to Kais Rona, MD, a bariatric surgeon of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA.'As a physician who has treated and continues to treat many patients with GLP-1 medications such as Ozempic, I found this study quite interesting,' Rona said. 'Although the data in this study cannot be extrapolated directly to humans, it does shed some light on potentially important physiologic effects of the medication.' 'The decrease in lean mass with GLP-1 use was associated with a lesser decrease in skeletal muscle mass and a greater decrease in the size of metabolically active organs such as the liver. This can have important physiologic effects on metabolism and overall health. We also see a decrease in liver mass in patients undergoing weight loss surgery, which often leads to beneficial health effects. Importantly, this study also highlights the importance of determining the functional impact of muscle loss and whether that is reflected in a loss of strength as well.'— Kais Rona, MD'It's extremely important to continue to study the potential side effects, including the loss of lean muscle mass, associated with GLP-1 medications as it can have major effects on our healthcare system as a whole,' Rona added. 'Furthermore, we need to continue to broaden our understanding of the physiologic effects of these medications to optimize patient safety and overall outcomes.' Rona said the next best research step would be to perform randomized-controlled trials in humans to further analyze the effects of GLP-1 medications on lean mass as well as skeletal muscle mass. 'It would be important to evaluate its effects on muscle strength as well as function,' he added. 'Also to determine whether certain areas of the body are more susceptible to muscle loss as well as identifying preventive strategies to combat muscle loss.'
